Cargando…

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis

AIMS: Levels of growth differentiation factor 15 (GDF-15), a cytokine secreted in response to cellular stress and inflammation, have been associated with multiple types of cardiovascular (CV) events. However, its comparative prognostic performance across different presentations of atherosclerotic ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Eri Toda, Morrow, David A, Guo, Jianping, Berg, David D, Blazing, Michael A, Bohula, Erin A, Bonaca, Marc P, Cannon, Christopher P, de Lemos, James A, Giugliano, Robert P, Jarolim, Petr, Kempf, Tibor, Kristin Newby, L, O’Donoghue, Michelle L, Pfeffer, Marc A, Rifai, Nader, Wiviott, Stephen D, Wollert, Kai C, Braunwald, Eugene, Sabatine, Marc S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066747/ https://www.ncbi.nlm.nih.gov/pubmed/36303404 http://dx.doi.org/10.1093/eurheartj/ehac577

Ejemplares similares

Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
por: Kato, Eri Toda, et al.
Publicado: (2017)

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2022)

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
por: Freedman, Benjamin L., et al.
Publicado: (2023)

Multimarker Risk Stratification in Patients With Acute Myocardial Infarction
por: O'Donoghue, Michelle L., et al.
Publicado: (2016)

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
por: Røysland, Ragnhild, et al.
Publicado: (2012)

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P‐TIMI 50
por: Berg, David D., et al.
Publicado: (2021)

Biomarker of Collagen Turnover (C‐Terminal Telopeptide) and Prognosis in Patients With Non‐ST‐Elevation Acute Coronary Syndromes
por: Zelniker, Thomas A., et al.
Publicado: (2019)

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT
por: Giugliano, Robert P., et al.
Publicado: (2020)

Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
por: Fanola, Christina L., et al.
Publicado: (2017)

Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long‐Term Follow‐Up After Acute Coronary Syndromes
por: Fanaroff, Alexander C., et al.
Publicado: (2017)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
por: Moura, Filipe A., et al.
Publicado: (2023)

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome
por: Correa, Simon, et al.
Publicado: (2018)

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
por: Berg, David D., et al.
Publicado: (2021)

Cardiovascular Events and Long‐Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE‐IT
por: Fordyce, Christopher B., et al.
Publicado: (2022)

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36
por: Zelniker, Thomas A., et al.
Publicado: (2021)

The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
por: Sarma, Amy, et al.
Publicado: (2014)

Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT
por: Shah, Nishant P., et al.
Publicado: (2023)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial
por: Gencer, Baris, et al.
Publicado: (2020)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Acute Dissection of the Descending Aorta: A Case Report and Review of the Literature
por: Bergmark, Brian A., et al.
Publicado: (2013)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
por: Magnani, Giulia, et al.
Publicado: (2021)

Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry
por: Bhatt, Ankeet S., et al.
Publicado: (2023)

How does the TRS 2°P score relate to real-world patients?
por: Bonaca, Marc P, et al.
Publicado: (2018)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid‐Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P‐TIMI 50 Trial
por: Gilchrist, Ian C., et al.
Publicado: (2021)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data
por: Rousset, Adrien, et al.
Publicado: (2021)

COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies
por: Atri, Deepak, et al.
Publicado: (2020)

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)

A current review of COVID-19 for the cardiovascular specialist
por: Lang, Joshua P., et al.
Publicado: (2020)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Studying the coagulopathy of COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2022)

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2016)

Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome
por: Kempf, Tibor, et al.
Publicado: (2013)

A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia
por: Cheng, Henry S., et al.
Publicado: (2023)

Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis
por: Cheng, Henry S., et al.
Publicado: (2023)

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?
por: Thuny, Franck, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7o3g3q62l12qv46hj0pegmlavf